Inify Laboratories announces final results of fully guaranteed private placement

Inify Laboratories completed a fully guaranteed private placement of 26,266,866 shares at an offer price of NOK 3.50, raising gross proceeds of NOK 91,934,031 to shore up liquidity following a slight fit-out delay and higher-than-expected investments for its UK establishment. Of these, 25,759,315 shares were allocated to valid applicants and 507,551 shares were allocated to guarantors Monsun AS (435,043) and Auris AS (72,508). Settlement is expected on or about 25 March 2026 with new shares tradable after registration by 30 March 2026; a separate repair issue of ~NOK 8 million will be offered to smaller existing shareholders. SB1 Markets acted as financial advisor and Schjødt as legal counsel.

Analysis

Market structure: The NOK 92m fully guaranteed placement and NOK 8m repair issue materially de-risks near-term liquidity and prevents an emergency equity drawdown; settlement/payment timelines (payment ~25 Mar 2026, registration by ~30 Mar 2026) create a known binary event that will reprice the stock once tradability clears. Winners are existing large shareholders/guarantors (Monsun AS, Auris AS) who demonstrated support; losers are short-term non-participating small holders diluted by the Repair Issue. The move modestly increases pricing power for Inify in tendering new UK contracts by funding fit-out, but overall competitive dynamics in diagnostics stay local — market-share shifts require execution over 12–24 months.

Risk assessment: Key tail risks are (1) ISP/FDI review that delays or blocks non-EU investors (notification thresholds at 10/20/30/50/65/90%), (2) further cost overruns in the UK expansion, and (3) registration delays at SCRO/Euroclear that freeze tradability past 30 Mar 2026. Immediate (days) risks center on market sentiment; short-term (weeks/months) on Repair Issue uptake and final register; long-term (12–24 months) on revenue ramp from UK labs and clinical validation of AI. Hidden dependencies: pathology revenue lags 6–12 months after lab opening and requires robust local referrals; reimbursement/regulatory shifts in UK could amplify downside.

Trade implications: Direct play is a conditional, small-sized long in INIFY (ticker INIFY) executed post-registration to avoid settlement freeze; target horizon 12 months to capture UK ramp. Use relative hedges vs. Nordic medtech small-cap exposure to neutralize beta; consider 9.9% ownership cap until ISP clears to avoid administrative sanctions. Options: if liquid, implement 9–15 month call spreads 25–40% OTM to limit premium and define downside.

Contrarian angle: The market may over-penalize dilution and short-term UK spend, creating buying opportunities once shares are tradable and FDI risk mitigated — insider guarantee reduces bankruptcy tail risk. Historical parallels: small diagnostics groups that completed capital raises and then rerated after facility ramp (~+30–80% within 12–18 months) if org execution held; downside is execution failure. Unintended consequence: aggressive repair allocations may depress free float and liquidity, making options/exit harder; size positions accordingly.

Key Decisions for Investors

• Establish a conditional long position in INIFY (ticker INIFY) sized 1–2% of portfolio only after confirmation of share registration with Euroclear/VPS (~by 30 Mar 2026). Target +40% upside over 12 months, set hard stop loss at -25% from entry to limit execution/expansion risk.
• If you are an existing shareholder eligible for the Repair Issue, subscribe pro-rata up to full entitlement between ~12–26 Jan 2026 to avoid >10% dilution; if not eligible, avoid accumulating to ≥10% ownership until ISP/FDI either takes no action or approves (prevents administrative fines).
• Implement a hedged pair: long INIFY 1–2% vs short equal notional exposure to a basket of Euronext Growth Oslo small-cap healthcare/medtech names (to neutralize Nordic small-cap beta). Rebalance after registration and quarterly thereafter.
• If options are available/liquid, buy a 9–15 month bull call spread (buy 25% OTM call, sell 50% OTM call) sized to cost ≤1% of portfolio to express asymmetric upside while capping premium; roll or close on positive proof points (first UK lab revenue within 6–12 months).
• Do not increase exposure above 9.9% until FDI/ISP clearance; monitor three triggers (FDI decision, SCRO registration, first UK monthly revenue print) and reassess allocation at each: reduce by 50% if any two triggers miss timelines by >60 days.